Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

NCT ID: NCT05703009

Last Updated: 2024-02-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-05
• Study Completion Date: 2024-01-22

Brief Summary

SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.

Detailed Description

This Phase 2 study will evaluate the efficacy and safety of sacrosidase and placebo in male and female subjects aged 18 years or older objectively diagnosed with fructan intolerance via fructan breath test within 6 months prior to informed consent and are negative for inflammatory bowel disease or low-grade GI bacterial infection, detected by fecal calprotectin test, celiac disease, detected by serology for anti-gluten protein antibodies, congenital sucrase-isomaltase deficiency (CSID), detected by sucrose hydrogen-methane breath test, and have a negative result for abnormal uncontrolled thyroid function, detected by the standard TSH blood test. This study will consist of a Screening Visit, Baseline Period, Treatment Period 1, Washout Period, and Treatment Period 2. Subjects will be required to attend 5 clinic visits during study participation. Subjects will be randomized in a 1:1 fashion to either receive sacrosidase or placebo during Treatment Period 1. Following a 7-day Washout Period, subjects will receive their crossover study medication for Treatment Period 2. Subjects will take their assigned study medication for 7 days during each Treatment Period.

Conditions

Fructan Intolerance

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment

Subjects will be randomized to take active treatment, sacrosidase, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.

Group Type: EXPERIMENTAL

Sacrosidase Oral Solution

Intervention Type: DRUG

Study drug

Placebo

Subjects will be randomized to take placebo treatment, sacrosidase placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

Sacrosidase Oral Solution

Study drug

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Other Intervention Names

sacrosidase

Eligibility Criteria

Inclusion Criteria

• Ability to comprehend and provide a signed and dated informed consent form
• Stated willingness to comply with all study procedures and attend all scheduled clinic visits, and continue participation for the duration of the study
• Ability to self-administer oral medication and willingness to adhere to the medication regimen
• Male or non-pregnant, non-lactating female, at least 18 years of age
• Sexually active women of childbearing potential must agree to use at least one reliable method of birth control while participating in the study
• Presence of fructan intolerance as determined by a positive result on a FBT within the last 6 months
• Subjects who are lactose intolerant agree to eliminate all lactose from their diet during the study
• Stated willingness to discontinue any medications to resolve GI symptoms (digestive enzymes, antacids, proton pump inhibitors, histamine-2 blockers, promotility agents, or anti-diarrheal agents, etc.), per the investigator's discretion.
• Stated willingness to discontinue any over the counter or prescribed oral nonsteroidal anti-inflammatory drugs (NSAIDs) during the study
• Per the discretion of the investigator, absence of any GI disorder other than a diagnosis of fructan intolerance

Exclusion Criteria

• History of inflammatory bowel disease or active low-grade GI bacterial infection, as diagnosed by the presence of fecal calprotectin
• History of celiac disease, as diagnosed by serology testing for anti-gluten protein antibodies
• History of CSID, as diagnosed by the sucrose hydrogen-methane breath test,
• Abnormal uncontrolled thyroid function, detected by abnormal TSH level in the blood
• Per the discretion of the investigator, history of a serious physical or mental disorder
• BMI greater than 30 kg/m2
• History of diabetes
• History of hypersensitivity to yeast, yeast products, glycerin (glycerol), or papain

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

QOL Medical, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Weng Tao, M.D., Ph. D

Role: PRINCIPAL_INVESTIGATOR

QOL Medical, LLC

Locations

Boston Specialists

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

SSDXA-14

Identifier Type: -

Identifier Source: org_study_id